Print Page   |   Contact Us   |   Sign In   |   Join
News and Press: Member Organization News

Armune BioScience, Inc. Announces an Investment by the U of M Investment Fund

Tuesday, September 06, 2016   (0 Comments)
Posted by: Kate Oesterle
Share |

Armune BioScience, the developer of APIFINY®, the only cancer specific, non-PSA blood test available to assess the risk for the presence of prostate cancer, today announced the University of Michigan MINTS program has recently participated in the company’s $5 million Series A investment round.

“We are excited to have the University of Michigan’s MINTS program participate in our Series A financing,” said David Esposito, President and Chief Executive Officer of Armune BioScience. “With over 7,000 billable APIFINY tests ordered since launch, this financing will help us prepare for the long term growth of the business. We look forward to the involvement of investment partners like the University of Michigan Investment Office in helping us to achieve our goals.”

“Through the Michigan Investment in New Technology Start-ups (MINTS) program, the University of Michigan Investment Office supports early stage companies working to commercialize University of Michigan technology,” commented Felicia D. David-Visser, CFA, Manager of Investments. “We are very excited to see the progress that Armune has made in the market and we are confident in the leadership team’s ability to deliver on key milestones important to the growth of the business.”

 

Read full press release.


Creating Value
by delivering business-critical resources & bottom line savings
Building Networks
by connecting Michigan's bio-industry one member at a time
Growing Talent
by creating opportunities that develop people & build organizations
Membership Software Powered by YourMembership.com®  ::  Legal